Prosecution Insights
Last updated: April 19, 2026

Examiner: OGUNBIYI, OLUWATOSIN A

Tech Center 1600 • Art Units: 1641 1645

This examiner grants 63% of resolved cases

Performance Statistics

63.3%
Allow Rate
+3.3% vs TC avg
959
Total Applications
+42.9%
Interview Lift
1145
Avg Prosecution Days
Based on 914 resolved cases, 2023–2026

Rejection Statute Breakdown

5.5%
§101 Eligibility
24.0%
§102 Novelty
26.4%
§103 Obviousness
26.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17672748 PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK Non-Final OA Takeda Pharmaceutical Company Limited
18693477 BACTERIOLYSIS METHOD, BACTERIOLYSIS AID, AND METHOD FOR DETERMINING THE PRESENCE OR ABSENCE OF BACTERIA Non-Final OA ASAHI KASEI KABUSHIKI KAISHA
18293016 MICROORGANISMS DISPLAYING VIRAL DECOY RECEPTORS Non-Final OA EVONIK OPERATIONS GMBH
18344790 SURFACE DISPLAYED FUSION PROTEINS Non-Final OA Clara Foods Co.
18696177 ESCHERICHIA COLI HAVING 3-HYDROXYPROPIONATE PRODUCTION ABILITY, WITH 3-HYDROXYPROPIONATE PRODUCTION GENE INSERTED INTO SAME, AND USE THEREOF Non-Final OA LG CHEM, LTD.
18701173 COMPOSITION FOR PREVENTING, TREATING OR ALLEVIATING RHEUMATOID ARTHRITIS COMPRISING PROPIONIBACTERIUM FREUDENREICHII MJ2 STRAIN AS AN ACTIVE INGREDIENT Non-Final OA KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
18472445 TARGETING THE IMMUNE SUPPRESSIVE TUMOR MICROENVIRONMENT Non-Final OA BROWN UNIVERSITY
18697325 ENGINEERED VECTORS AND ORGANISMS CONTAINING THE SAME FOR ISOFLAVONE CONVERSION IN THE GUT Non-Final OA Board of Regents, The University of Texas System
18028477 VARIANT STAPHYLOCOCCUS AUREUS LUKA AND LUKB POLYPEPTIDES AND VACCINE COMPOSITIONS Final Rejection NEW YORK UNIVERSITY
17787091 COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST STAPHYLOCOCCUS AUREUS Final Rejection Washington University
17434349 TREATMENT OF BENIGN NERVOUS SYSTEM TUMORS USING ATTENUATED SALMONELLA TYPHIMURIUM Non-Final OA The General Hospital Corporation
18695708 FISH REARING COMPOSITION, AND COMPOSITION FOR PREVENTING OR TREATING FISH DISEASES Non-Final OA SUMITOMO CHEMICAL COMPANY, LIMITED
18935074 METHODS AND USES OF MICROBIOME COMPOSITIONS Non-Final OA MarvelBiome, Inc.
18273779 COMPOSITION FOR INCREASING MUSCLE MASS AND SUPPRESSING A DECREASE IN MUSCLE MASS, AND COMPOSITION FOR INCREASING MUSCLE MASS AND SUPPRESSING MUSCLE ATROPHY Non-Final OA DIC Corporation
18252124 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof Non-Final OA Pfizer Inc.
18255275 COMPOSITION FOR PREVENTING OR TREATING DETERIORATION IN BRAIN FUNCTION OR MAINTAINING OR IMPROVING BRAIN FUNCTION Non-Final OA TOKYO INSTITUTE OF TECHNOLOGY
18698993 ASSOCIATION OF A FAECALIBACTERIUM PRAUSNITZII STRAIN AND ANTI-PD-1, ANTI-PD-L1 OR ANTI-CTLA-4 ANTIBODIES FOR THE TREATMENT OF CANCER Non-Final OA EXELIOM BIOSCIENCES
18695879 BIO-FUNGICIDES FORMULATIONS FOR INHIBITING PHYTOPHTHORA INFESTANS AND METHOD THEREOF Non-Final OA TAMIL NADU AGRICULTURAL UNIVERSITY
18267687 COMPOSITION FOR IMPROVING INFLAMMATION OF BRAIN TISSUE Final Rejection MEIJI CO., LTD.
17906471 T-CELL BISPECIFIC BINDING PROTEINS Non-Final OA CRISPR THERAPEUTICS AG
18001498 MODIFIED EXOTOXIN A PROTEINS Non-Final OA GlaxoSmithKline Biologicals SA
17998194 PROTEINS AND NUCLEIC ACIDS FOR EHRLICHIA DIAGNOSIS AND VACCINATION Non-Final OA Research Development Foundation
18291147 Recombinant Mycobacterium as an Immunotherapeutic Agent for the Second-Line Therapy of Bladder Carcinoma Non-Final OA Serum Institute of India Pvt. Ltd.
18414311 Albumin-Free Botulinum Toxin Formulations Non-Final OA REVANCE THERAPEUTICS, INC.
18264703 PROBIOTIC COMPOSITION FOR THE TREATMENT OF COVID-19 Final Rejection AB-BIOTICS, S.A.
18258950 USE OF LACTIC ACID BACTERIA TO INHIBIT METHANOGEN GROWTH OR REDUCE METHANE EMISSIONS Final Rejection Fonterra Co-Operative Group Limited
18368505 VACCINE COMPOSITIONS AND METHODS OF USING THE SAME Non-Final OA The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
18550036 NOVEL VACCINE FORMULATIONS FOR MYCOBACTERIUM TUBERCULOSIS AND USE OF THEREOF Non-Final OA HOUSTON METHODIST RESEARCH INSTITUTE
18549804 COMPOSITION AND AMELIORATING AGENT HAVING INFLAMMATION REDUCING EFFECT Non-Final OA KYOWA HAKKO BIO CO., LTD.
18281265 ANTIBACTERIAL METHODS & CELLS Non-Final OA Folium Food Science Limited

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month